您的位置: 首页 > 农业专利 > 详情页

用SIRPα-FC融合蛋白處理CD47+疾病細胞
专利权人:
TRILLIUM THERAPEUTICS INC.
发明人:
UGER, Robert Adam,SLAVOVA-PETROVA, Penka Slavtcheva,PANG, Xinli
申请号:
HK16105678.0
公开号:
HK1217716A
申请日:
2016.05.18
申请国别(地区):
HK
年份:
2017
代理人:
摘要:
A human SIRPα fusion protein useful to inhibit the growth and/or proliferation of a CD47+ disease cell, the fusion protein having negligible CD47 agonism and negligible red blood cell binding, the fusion protein comprising a human SIRPα domain effective to bind human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRPα, and a human IgG constant region (Fc) having effector function, the potency of the fusion protein being at least 5 fold greater than the potency of a SIRPaFc fusion formed from an Fc region lacking effector function, wherein the human SIRPα domain is an IgV domain comprising residues 32-137 [SEQ ID No.1] of human SIRPα variant 2.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充